Computational, In Vitro, and In Vivo Evaluation of Benzimidazole–Pyrazole Hybrid Scaffolds as Multi‐Target Anti‐Ulcer Agents
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.71698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Hafiz Aamir Ali Kharl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Pyrazoles, Benzimidazoles, Anti-Ulcer Agents, Stomach Ulcer. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Funding Program, King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Peptic ulcer disease (PUD) continues to be an important gastrointestinal condition attributed to Helicobacter pylori infection, usage of nonsteroidal anti‐inflammatory drugs, oxidative stress, and inflammatory mediators. Although there are available treatments for this condition, side effects, relapse, and safety issues call for development of new multi‐target anti‐ulcer compounds. In this research, a group of benzimidazole‐pyrazole analogs (5a–5j) was designed, synthesized, and studied with the aid of computational and experimental methods. Molecular docking into H + /K + ‐ATPase (PDB ID: 5YLU) and COX‐2 (PDB ID: 3LN1) enzymes predicted high affinity of these compounds with docking scores of −9.4 and −9.3 kcal/mol for compounds 5i and 5e, respectively, higher than those obtained for the reference drugs omeprazole and celecoxib. The inhibition of the gastric H + /K + ‐ATPase enzyme was also observed in vitro, with compounds 5i and 5e having better inhibitory effects. Studies on the ethanol and indomethacin‐induced gastric ulceration models demonstrated good inhibitory effects of these compounds. Biochemical analysis showed that these analogs significantly decreased the levels of TNF‐α, COX‐2, myeloperoxidase, and malondialdehyde and increased prostaglandin E 2 . Acute oral toxicity studies indicated no observable toxicity at 100 mg/kg. Collectively, these findings identify compounds 5i and 5e as promising multifunctional gastroprotective candidates warranting further pharmacological investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
- Department of Pharmacy, Faculty of Health & Pharmaceutical Sciences, University of Agriculture, Faisalabad, Pakistan.
- Department of Physiology, Government College University Faisalabad, Faisalabad, Pakistan.
ORCID-Profile: Hafiz Aamir Ali Kharl, Humaira Nadeem, Mohammad Shamsul Ola, Sara Aiman, Humaira Muzaffar, Syed Muzzammil Masaud
Förderung
- Research Funding Program, King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Kharl, H. A. A., Malik, A., Nadeem, H., Ola, M. S., Aiman, S., Khan, A. U., Farooq, M. A., Muzaffar, H., & Masaud, S. M. (2026). Computational, In Vitro, and In Vivo Evaluation of Benzimidazole–Pyrazole Hybrid Scaffolds as Multi‐Target Anti‐Ulcer Agents. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71698
Vancouver
Kharl HAA, Malik A, Nadeem H, Ola MS, Aiman S, Khan AU, et al. Computational, In Vitro, and In Vivo Evaluation of Benzimidazole–Pyrazole Hybrid Scaffolds as Multi‐Target Anti‐Ulcer Agents. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71698
BibTeX
@article{Kharl2026,
author = {Kharl, Hafiz Aamir Ali and Malik, Abdul and Nadeem, Humaira and Ola, Mohammad Shamsul and Aiman, Sara and Khan, Arif Ullah and Farooq, Muhammad Akmal and Muzaffar, Humaira and Masaud, Syed Muzzammil},
title = {Computational, In Vitro, and In Vivo Evaluation of Benzimidazole–Pyrazole Hybrid Scaffolds as Multi‐Target Anti‐Ulcer Agents},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.71698}
}
EUVIMED